All In Biotech

Drug Trial Radar · NCT01462942

Long-term Efficacy and Safety of Aclidinium Bromide/Formoterol Fumarate Fixed-Dose Combination

Efficacy and Safety of Aclidinium Bromide/Formoterol Fumarate Fixed-dose Combinations Compared With Individual Components and Placebo When Administered to Patients With Stable Chronic Obstructive Pulmonary Disease.

Last checked: Nov 19, 2026Latest source record: Feb 15, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 2,443 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

2,443

Actual

Start

Oct 2011

Primary completion

Jan 2013

Study completion Jan 2013

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Nov 1, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 40 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objective is to provide data supporting the use of LAS40464 as an efficacious and safe maintenance bronchodilator treatment of patients with Chronic Obstructive Pulmonary Disease (COPD).

Conditions

  • Chronic Obstructive Pulmonary Disease (COPD)

Interventions

  • Aclidinium Bromide/Formoterol FumarateDrug

    Inhaled Aclidinium/formoterol Fixed Dose Combination (FDC) low dose (400/6 μg), twice per day

  • Aclidinium Bromide/Formoterol FumarateDrug

    Inhaled Aclidinium/formoterol FDC high dose (400/12 μg), twice per day

  • Aclidinium BromideDrug

    Inhaled Aclidinium 400 μg, twice per day

  • PlaceboDrug

    Inhaled dose-matched placebo, twice per day

  • Formoterol FumarateDrug

    Inhaled Formoterol 12 μg, twice per day

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in 1-hour Morning Post-dose Forced Expiratory Volume in One Second (FEV1)Time frame: Baseline and Week 24
  2. Change From Baseline in Morning Pre-dose (Trough) Forced Expiratory Volume in One Second (FEV1)Time frame: Baseline and Week 24

Locations

197 sites in 22 countries. Site status is shown where the registry gives one.

  • Almirall Investigational Site #2

    Graz, Austria

  • Almirall Investigational Site #3

    Salzburg, Austria

  • Almirall Investigational Site #3

    Edegem, Belgium

  • Almirall Investigational Site #2

    Genk, Belgium

  • Almirall Investigational Site #6

    Rousse, Bulgaria

  • Almirall Investigational Site #10

    Sevlievo, Bulgaria

  • Almirall Investigational Site #8

    Sofia, Bulgaria

  • Almirall Investigational Site #2

    Sofia, Bulgaria

  • Almirall Investigational Site #11

    Sofia, Bulgaria

  • Almirall Investigational Site #2

    Zagreb, Croatia

  • Almirall Investigational Site #4

    Zagreb, Croatia

  • Almirall Investigational Site #8

    Brno, Czechia

  • Almirall Investigational Site #3

    Jindřichův Hradec, Czechia

  • Almirall Investigational Site #10

    Karlovy Vary, Czechia

  • Almirall Investigational Site #9

    Liberec, Czechia

  • Almirall Investigational Site #16

    Ostrava Hrabuvka, Czechia

  • Almirall Investigational Site #2

    Prague, Czechia

  • Almirall Investigational Site #12

    Prague, Czechia

  • Almirall Investigational Site #15

    Prague, Czechia

  • Almirall Investigational Site #14

    Prague, Czechia

  • Almirall Investigational Site #6

    Praha 5 - Radotin, Czechia

  • Almirall Investigational Site #11

    Strakonice, Czechia

  • Almirall Investigational Site #1

    Tábor, Czechia

  • Almirall Investigational Site #4

    Hillerød, Denmark

  • Almirall Investigational Site #1

    København NV, Denmark

  • Almirall Investigational Site #5

    Odense, Denmark

  • Almirall Investigational Site #2

    Silkeborg, Denmark

  • Almirall Investigational Site #7

    Espoo, Finland

  • Almirall Investigational Site #8

    Jyväskylä, Finland

  • Almirall Investigational Site #1

    Tampere, Finland

  • Almirall Investigational Site #6

    Tampere, Finland

  • Almirall Investigational Site #3

    Turku, Finland

  • Almirall Investigational Site #6

    Lille, France

  • Almirall Investigational Site #10

    Marseille, France

  • Almirall Investigational Site #11

    Montpellier, France

  • Almirall Investigational Site #1

    Pessac, France

  • Almirall Investigational Site #3

    Rennes, France

  • Almirall Investigational Site #8

    Toulouse, France

  • Almirall Investigational Site #12

    Vieux-Condé, France

  • Almirall Investigational Site #2

    Berlin, Germany

Showing 40 of 197 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.